(N) - 甲甲氨基氨酸作为单氨基载体全抑制剂:扩大了N6组用于比托普稳定
Dilip K Tosh1, Matteo Pavan1, Laura B Kozell2
1Molecular Recognition Section, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.
European journal of medicinal chemistry
|September 26, 2025
概括
研究人员修改了核糖类类似物,以研究它们对人类多巴胺转运体 (hDAT) 的影响. 较小的N6修改增强了hDAT结合,而较大的N6-(ω-phenyl-alkyl) 组通过进入新区域来抑制结合.
科学领域:
- 神经科学是一个神经科学.
- 药用化学 医学化学
- 结构生物学 结构生物学
背景情况:
- 人类多巴胺转运体 (hDAT) 结构,稳定通过一个全抑制剂,为了解转运体-连接体相互作用提供了基础.
- 核糖类类似物正在被探索,因为它们有可能调节单胺转运器活性.
研究的目的:
- 合成和评估新型北 (N) - 甲甲 - 氨酸类似物对它们对hDAT,上腺素转运体 (NET) 和血清素转运体 (SERT) 结合的影响.
- 研究这些类型的结构-活性关系 (SAR),重点关注N6,C2和4'位置的修饰.
- 用计算方法阐明强效类型的结合模式.
主要方法:
- 合成具有多种N6,C2和4'替代的N-甲碳-腺酸相似物.
- 放射性结定量测试以确定hDAT,NET和SERT的抑制常量 (Ki) 和增强效应.
- 使用面向外的hDAT冷EM结构进行分子对接和分子动力学模拟.
主要成果:
- 微小的N6修改,如N6-甲基和N6-cyclopropyl,显著增强hDAT放射性体的结合 (高达≥500%).
- N6-(ω-phenyl-alkyl) 组通过与远端结合区域相互作用来诱导DAT结合抑制,在五个甲基中具有最佳的链长.
- 特定的类似物,如N6-(6-Phenylhexyl)-2-化合物53和54,证明了强大的DAT抑制 (Ki值分别为0.89μM和0.40μM).
- 分子建模预测了hDAT.中的N6-(ω-phenyl-alkyl) 替代剂和关键芳香残留物 (F208,H375) 之间的π-π相互作用.
结论:
- 该研究描述了N-甲卡巴-腺酸相似物的载体SAR,揭示了hDAT结合增强和抑制的双重效应.
- N6-(ω-phenyl-alkyl) 替代剂通过引入独特的远端结合口袋,代表了开发DAT抑制剂的有希望的策略.
- 来自对接和MD模拟的结构洞察力为设计下一代DAT调制器提供了基础.
更多相关视频
相关概念视频
Adrenergic Agonists: Indirect-Acting Agents
2.6K
Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral...
2.6K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.8K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.8K
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
2.0K
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
2.0K
Direct-Acting Cholinergic Agonists: Therapeutic Uses
1.6K
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren...
1.6K
Drugs Affecting Neurotransmitter Synthesis
2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
1.2K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.2K


